1. Home
  2. TECH vs QGEN Comparison

TECH vs QGEN Comparison

Compare TECH & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$55.53

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Logo Qiagen N.V.

QGEN

Qiagen N.V.

HOLD

Current Price

$34.45

Market Cap

10.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECH
QGEN
Founded
1976
1986
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
10.2B
IPO Year
1995
1998

Fundamental Metrics

Financial Performance
Metric
TECH
QGEN
Price
$55.53
$34.45
Analyst Decision
Strong Buy
Buy
Analyst Count
11
8
Target Price
$71.82
$45.76
AVG Volume (30 Days)
1.8M
1.7M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
0.62%
7.17%
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$1,219,635,000.00
N/A
Revenue This Year
$2.49
$8.18
Revenue Next Year
$6.40
$5.71
P/E Ratio
$106.04
$24.01
Revenue Growth
5.23
N/A
52 Week Low
$46.05
$33.17
52 Week High
$72.16
$57.82

Technical Indicators

Market Signals
Indicator
TECH
QGEN
Relative Strength Index (RSI) 50.16 24.73
Support Level $49.55 N/A
Resistance Level $58.04 $49.16
Average True Range (ATR) 2.73 0.93
MACD -0.40 -0.61
Stochastic Oscillator 38.90 12.50

Price Performance

Historical Comparison
TECH
QGEN

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About QGEN Qiagen N.V.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Share on Social Networks: